Showing results (51-60 of 109) with videos related to
Sort By:
Pageof 11
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|October 13, 2021
Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)Takehiro Kawashiri, Daisuke Kobayashi, Mayako Uchida, et al.Scientific Reports|April 27, 2021
Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndromeShiori Hiromoto, Takehiro Kawashiri, Natsumi Yamanaka, et al.Journal of Pharmaceutical Health Care and Sciences|December 20, 2025
Evaluation of the pSMILE (Palliative care-Situational Motivating Interactive Learning and Education) educational program based on web-based and face-to-face workshops for palliative care pharmacistsMegumi Kabeya, Mayako Uchida, Masahiko Amagawa, et al.International Journal of Molecular Sciences|February 12, 2021
Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical EvidenceTakehiro Kawashiri, Keisuke Mine, Daisuke Kobayashi, et al.Therapeutics and Clinical Risk Management|January 15, 2019
Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report databaseAyaka Inada, Keiko Hosohata, Saki Oyama, et al.Biological & Pharmaceutical Bulletin|November 2, 2018
Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis ToolMayako Uchida, Tsutomu Nakamura, Takahiro Shima, et al.Biological & Pharmaceutical Bulletin|April 19, 2019
A Nationwide Survey of Community Pharmacist Contributions to Polypharmacy in Opioid-Using and Non-using Cancer Patients in JapanShinya Suzuki, Mayako Uchida, Yukio Suga, et al.Cancer Immunology, Immunotherapy : CII|March 26, 2026
Clinical characteristics, prognostic factors, and feasibility of ICI continuation in immune checkpoint inhibitor-related pneumonitisKeisuke Masumoto, Kazuya Tsubouchi, Ryosuke Matsukane, et al.Therapeutics and Clinical Risk Management|September 21, 2018
Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system databaseSaki Oyama, Keiko Hosohata, Ayaka Inada, et al.International Journal of Cancer|December 15, 2005
Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancerHideaki Yahata, Mami Saito, Toshiaki Sendo, et al.Pageof 11